Wave Life Sciences Statistics
Share Statistics
Wave Life Sciences has 154.09M
shares outstanding. The number of shares has increased by 25.32%
in one year.
| Shares Outstanding | 154.09M |
| Shares Change (YoY) | 25.32% |
| Shares Change (QoQ) | 0.63% |
| Owned by Institutions (%) | 97.79% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 13.24M, so 8.59% of the outstanding
shares have been sold short.
| Short Interest | 13.24M |
| Short % of Shares Out | 8.59% |
| Short % of Float | 11.76% |
| Short Ratio (days to cover) | 9.48 |
Valuation Ratios
The PE ratio is -17.63 and the forward
PE ratio is -6.77.
Wave Life Sciences's PEG ratio is
-0.6.
| PE Ratio | -17.63 |
| Forward PE | -6.77 |
| PS Ratio | 15.79 |
| Forward PS | 2.3 |
| PB Ratio | 8.16 |
| P/FCF Ratio | -11.26 |
| PEG Ratio | -0.6 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Wave Life Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.89,
with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.89 |
| Quick Ratio | 2.89 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.25 |
| Debt / FCF | -0.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $377,358.89 |
| Profits Per Employee | $-338,006.97 |
| Employee Count | 287 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 17.97% in the
last 52 weeks. The beta is -0.92, so Wave Life Sciences's
price volatility has been lower than the market average.
| Beta | -0.92 |
| 52-Week Price Change | 17.97% |
| 50-Day Moving Average | 8.06 |
| 200-Day Moving Average | 9.94 |
| Relative Strength Index (RSI) | 42.88 |
| Average Volume (20 Days) | 1,438,639 |
Income Statement
In the last 12 months, Wave Life Sciences had revenue of 108.3M
and earned -97.01M
in profits. Earnings per share was -0.7.
| Revenue | 108.3M |
| Gross Profit | 99.64M |
| Operating Income | -110.4M |
| Net Income | -97.01M |
| EBITDA | -101.74M |
| EBIT | -110.4M |
| Earnings Per Share (EPS) | -0.7 |
Full Income StatementBalance Sheet
The company has 302.08M in cash and 25.4M in
debt, giving a net cash position of 276.67M.
| Cash & Cash Equivalents | 302.08M |
| Total Debt | 25.4M |
| Net Cash | 276.67M |
| Retained Earnings | -1.12B |
| Total Assets | 352.21M |
| Working Capital | 209.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -151.03M
and capital expenditures -938K, giving a free cash flow of -151.96M.
| Operating Cash Flow | -151.03M |
| Capital Expenditures | -938K |
| Free Cash Flow | -151.96M |
| FCF Per Share | -1.1 |
Full Cash Flow StatementMargins
Gross margin is 92%, with operating and profit margins of -101.94% and -89.57%.
| Gross Margin | 92% |
| Operating Margin | -101.94% |
| Pretax Margin | -89.57% |
| Profit Margin | -89.57% |
| EBITDA Margin | -93.94% |
| EBIT Margin | -101.94% |
| FCF Margin | -140.32% |
